The vascular endothelial growth factor (VEGF) antagonist, bevacizumab, combined with chemotherapy, also shows positive clinical effects in patients with NSCLC CNS metastasis without driver mutations [54,55,56]. Here, VEGFA is linked to non-small cell lung carcinoma.